Apollo Endosurgery (APEN) to Release Quarterly Earnings on Monday

Apollo Endosurgery (NASDAQ:APEN) is set to issue its quarterly earnings data before the market opens on Monday, March 18th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

Shares of NASDAQ:APEN opened at $3.32 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.42 and a quick ratio of 1.81. The stock has a market cap of $71.59 million, a price-to-earnings ratio of -1.65 and a beta of 0.72. Apollo Endosurgery has a 1-year low of $3.02 and a 1-year high of $9.65.

In other news, major shareholder Stonepine Capital, L.P. sold 250,000 shares of the company’s stock in a transaction dated Thursday, December 27th. The stock was sold at an average price of $3.00, for a total value of $750,000.00. Following the completion of the sale, the insider now directly owns 2,185,426 shares of the company’s stock, valued at approximately $6,556,278. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 52.80% of the company’s stock.

A hedge fund recently raised its stake in Apollo Endosurgery stock. Dimensional Fund Advisors LP lifted its holdings in Apollo Endosurgery Inc (NASDAQ:APEN) by 5.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 123,117 shares of the biotechnology company’s stock after purchasing an additional 6,551 shares during the quarter. Dimensional Fund Advisors LP owned about 0.56% of Apollo Endosurgery worth $425,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 39.30% of the company’s stock.

APEN has been the subject of a number of recent analyst reports. Zacks Investment Research cut Apollo Endosurgery from a “hold” rating to a “sell” rating in a research note on Friday, December 21st. Northland Securities raised Apollo Endosurgery from an “under perform” rating to a “market perform” rating and set a $3.00 price target for the company in a research note on Wednesday, January 2nd. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Apollo Endosurgery has a consensus rating of “Hold” and an average target price of $4.69.

WARNING: “Apollo Endosurgery (APEN) to Release Quarterly Earnings on Monday” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://sportsperspectives.com/2019/03/16/apollo-endosurgery-apen-to-release-quarterly-earnings-on-monday.html.

About Apollo Endosurgery

Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. It develops and distributes devices for minimally invasive surgical and non-surgical bariatric and gastrointestinal procedures that are used by surgeons and gastroenterologists in various settings to provide interventional therapy to patients who suffer from obesity and various co-morbidities associated with obesity, as well as treat various other gastrointestinal conditions.

Further Reading: Stock Selection – What is cash flow?

Earnings History for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.